Name: Epigenetic Cancer Therapy (Translational Epigenetics) (en Inglés)
Price: 580.62 PEN
Availability: InStock
Author: Gray, Steven
ISBN: 9780323913676

portada Epigenetic Cancer Therapy (Translational Epigenetics) (en Inglés)

Formato

Libro Físico

Ilustrado por

Steven Gray

Editorial

Academic Press

Autor

Gray, Steven

Idioma

Inglés

N° páginas

772

Encuadernación

Tapa Blanda

Dimensiones

23.5 x 19.1 x 3.9 cm

Peso

1.30 kg.

ISBN13

9780323913676

N° edición

0002

Categorías

Oncología
Genética (no médica)
Biología molecular

Epigenetic Cancer Therapy (Translational Epigenetics) (en Inglés)

Steven Gray (Ilustrado por) · Academic Press · Tapa Blanda

Libro Físico

S/ 580,62

S/ 1.161,25

Ahorras: S/ 580,62

50% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 12 de Junio y el Jueves 27 de Junio.

Lo recibirás en cualquier lugar de Perú entre 2 y 5 días hábiles luego del envío.

Reseña del libro "Epigenetic Cancer Therapy (Translational Epigenetics) (en Inglés)"

Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use. Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.